Acquired
Novo Nordisk (Ozempic)
David Rosenthal
But of course, everybody knows about these trials going on for weight loss and the ability to lose weight. It hits the market, and it is an enormous hit. It doesn't just overtake Bayeta as the leading GLP-1 drug on the market for diabetes. It massively expands the market. So year one, in the first year that it's on the market, Victoza does roughly $300 million in sales.
0
💬
0
Comments
Log in to comment.
There are no comments yet.